Ascendis Pharma Stock Price, News & Analysis

Ascendis Pharma A/S (Nasdaq: ASND) has launched Outgrow GHD, an online resource tailored for caregivers of children with growth hormone deficiency (GHD) in the U.S. The initiative aims to improve awareness and support for families navigating challenges associated with GHD. The platform offers educational materials, tools for engagement, and a quiz to discover parenting styles related to GHD.

The resource highlights the need for community support among families affected by rare diseases and will expand to include additional topics relevant to GHD management.

Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 3:40 p.m. Eastern Time. The presentation will include a business overview and an update on the company's product pipeline, which focuses on addressing unmet medical needs using its innovative TransCon technologies. A live webcast of the event will be accessible through the Ascendis Pharma website, with a replay available for 30 days following the event.

Ascendis Pharma A/S (Nasdaq: ASND) provided an update at the J.P. Morgan Healthcare Conference regarding its strategic roadmap, Vision 3x3. The company anticipates significant milestones in 2021, including advancing five independent TransCon product candidates into clinical development. Key highlights include the expected FDA PDUFA date for TransCon hGH on June 25, 2021, and potential MAA approval in Europe for pediatric growth hormone deficiency by Q4 2021. Additionally, clinical trials for TransCon PTH and TransCon CNP are ongoing, with results expected later this year.

VISEN Pharmaceuticals has secured $150 million in Series B funding, led by Sequoia China, to enhance its clinical development and commercialization efforts in Greater China. This financing round attracted participation from notable investors including OrbiMed and Cormorant. The funds will accelerate development of key endocrinology drug candidates like TransCon hGH and TransCon CNP, which address significant unmet medical needs in the region. CEO Pony Lu emphasized the ongoing Phase 3 study and IND approval as milestones for the company's innovative pipeline.

Ascendis Pharma A/S (Nasdaq: ASND) announced a $12.5 million equity investment in VISEN Pharmaceuticals as part of VISEN's $150 million Series B financing. This move is aligned with Ascendis' Vision 3x3 strategy, aimed at enhancing the global reach of its TransCon endocrinology products. Ascendis retains approximately 44% ownership of VISEN post-financing and expects a non-cash gain in Q1 2021. Key leadership from Ascendis will join VISEN's board to streamline collaboration in advancing clinical pipelines.

Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the 39th Annual J.P. Morgan Healthcare Conference to be held virtually on January 11, 2021, at 11:40 a.m. Eastern Time. During the event, company executives will provide an overview and updates on the company's pipeline programs, which focus on addressing unmet medical needs through innovative TransCon technologies. The webcast will be accessible on the company's website, with a replay available for 30 days following the conference.

Ascendis Pharma A/S (Nasdaq: ASND) announced the filing of an investigational new drug (IND) application for its TransCon TLR7/8 Agonist with the U.S. FDA. This long-acting prodrug is designed for intratumoral injection, aiming to offer sustained release of resiquimod, enhancing immune response against cancer while minimizing systemic exposure. The company emphasizes this milestone as a potential shift in cancer treatment, leveraging the immune system to target tumors more effectively.

Ascendis Pharma (Nasdaq: ASND) announced a board transition with Michael Wolf Jensen stepping down as Chair at the 2021 AGM but remaining as SVP and Chief Legal Officer. The Board intends to appoint Dr. Albert Cha as the new Chair. Jensen has been with the company since 2008, guiding its transformation into a global organization. Dr. Cha has been on the Board since 2014 and has experience in healthcare investment. Ascendis continues to innovate with its TransCon technologies, focusing on rare diseases and expanding into oncology.

Ascendis Pharma A/S (Nasdaq: ASND) announced its participation in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 3, 2020. Executives will provide an update on the company's pipeline and business overview. The event will be streamed live, with a replay available for 30 days on the company’s website. Ascendis is focused on developing innovative therapies using its TransCon technologies, currently advancing clinical programs in endocrinology and oncology, while expanding into additional therapeutic areas to address unmet patient needs.